Quick Answer
Benitec Biopharma Inc. reported Cash and Equivalents of $97.74 million for fiscal year 2025.
Benitec Biopharma Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $97.74M | +92.2% |
| 2024 | $50.87M | +1953.5% |
| 2023 | $2.48M | -39.0% |
| 2022 | $4.06M | -79.5% |
| 2021 | $19.77M | +101.7% |
| 2020 | $9.80M | -37.6% |
| 2019 | $15.72M | +32.3% |
| 2018 | $11.88M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | $188.79M | +141.2% | +99.8% |
| September 30, 2025 | $94.48M | +39.3% | -3.3% |
| June 30, 2025 | $97.74M | +92.2% | -5.6% |
| March 31, 2025 | $103.58M | — | +32.3% |
| December 31, 2024 | $78.28M | +284.2% | +15.4% |
| September 30, 2024 | $67.84M | +162.3% | +33.4% |
| June 30, 2024 | $50.87M | +1953.5% | +149.7% |
| December 31, 2023 | $20.37M | +93.4% | -21.2% |
- Benitec Biopharma Inc. showed an increase of +92.2% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2018–2025 period, Benitec Biopharma Inc.’s cash and equivalents has grown by 722.8% (from $11.88 million to $97.74 million).
- The most recent figure is from Benitec Biopharma Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on September 22, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: